Sana Biotechnology, Inc.
Close on Oct 19, 2026
- Market cap
- $680.03M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 5, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 10, 2026 | After market close | – | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 11, 2026 | After market close | – | $-0.17 | $-0.14 |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 3, 2026 | After market close | – | $-0.21 | $-0.16 |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 6, 2025 | After market close | – | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 11, 2025 | After market close | – | $0.39 | $0.16 |
| Q1 FY2025 Ended Mar 31, 2025 | May 8, 2025 | After market close | – | $0.21 | $0.20 |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 17, 2025 | After market close | – | $-0.21 | $-0.23 |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 8, 2024 | Before market open | – | $-0.25 | $-0.27 |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 8, 2024 | After market close | – | $-0.21 | $-0.32 |
| Q1 FY2024 Ended Mar 31, 2024 | May 8, 2024 | After market close | – | $0.49 | $0.32 |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 29, 2024 | After market close | – | $-0.45 | $-0.35 |
Press releases
Announcements Sana Biotechnology filed with the SEC
Sana Biotechnology Reports Second Quarter 2026 Financial Results and Business Updates
Results of operations · EX-99.1 to Form 8-K
Sana Biotechnology Reports First Quarter 2026 Financial Results and Business Updates
Results of operations · EX-99.1 to Form 8-K
Sana Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates
Results of operations · Other events · EX-99.1 to Form 8-K
Sana Biotechnology Appoints Brian Piper as Executive Vice President, Chief Financial Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Corporate Presentation January 2026 Exhibit 99.1
Regulation FD disclosure · EX-99.1 to Form 8-K
Sana Biotechnology Reports Third Quarter 2025 Financial Results and Business Updates
Results of operations · EX-99.1 to Form 8-K
Sana Biotechnology Reports Second Quarter 2025 Financial Results and Business Updates
Results of operations · EX-99.1 to Form 8-K
Sana Biotechnology Announces Pricing of Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
Sana Biotechnology Reports First Quarter 2025 Financial Results and Business Updates
Results of operations · Other events · EX-99.1 to Form 8-K
Sana Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates
Results of operations · EX-99.1 to Form 8-K
“design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,”
Regulation FD disclosure · EX-99.1 to Form 8-K
Sana Biotechnology Reports Third Quarter 2024 Financial Results and Business Updates
Results of operations · EX-99.1 to Form 8-K
Sana Biotechnology Reports Second Quarter 2024 Financial Results and Business Updates
Results of operations · EX-99.1 to Form 8-K
Sana Biotechnology Reports First Quarter 2024 Financial Results and Business Updates
Results of operations · EX-99.1 to Form 8-K
Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
Results of operations · EX-99.1 to Form 8-K
Sana Biotechnology Announces Pricing of Upsized Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
We were founded on the belief
Results of operations · Other events · EX-99.1 to Form 8-K
“design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,”
Regulation FD disclosure · EX-99.1 to Form 8-K
“design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,”
Regulation FD disclosure · EX-99.1 to Form 8-K
Sana Biotechnology Reports Third Quarter 2023 Financial Results and Business Updates
Results of operations · EX-99.1 to Form 8-K
Sana Biotechnology Announces Increased Focus on Hypoimmune-Related Pipeline with the Potential to Deliver Clinical Proof of Concept Data
Exit or restructuring costs · Regulation FD disclosure · EX-99.1 to Form 8-K
“design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,”
Exit or restructuring costs · Regulation FD disclosure · EX-99.2 to Form 8-K
Corporate Presentation September 2023 Exhibit 99.1
Regulation FD disclosure · EX-99.1 to Form 8-K
Sana Biotechnology Reports Second Quarter 2023 Financial Results and Business Updates
Results of operations · EX-99.1 to Form 8-K
Corporate Presentation June 2023 Exhibit 99.1
Regulation FD disclosure · EX-99.1 to Form 8-K
Sana Biotechnology Reports First Quarter 2023 Financial Results and Business Updates
Results of operations · EX-99.1 to Form 8-K
Sana Biotechnology Announces the Appointment of Two Pioneers in Drug Discovery and Development to Lead its R&D Organization
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Sana Biotechnology Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates
Results of operations · EX-99.1 to Form 8-K
Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for
Other events · EX-99.1 to Form 8-K
Corporate Presentation January 2023 Sana Biotechnology TM Exhibit 99.1
Regulation FD disclosure · EX-99.1 to Form 8-K
Sana Biotechnology Reports Third Quarter 2022 Financial Results and Business Updates
Results of operations · EX-99.1 to Form 8-K
Sana Biotechnology Reports Second Quarter 2022 Financial Results and Business Updates
Results of operations · EX-99.1 to Form 8-K
Corporate Presentation June 2022 Exhibit 99.1
Regulation FD disclosure · EX-99.1 to Form 8-K
Sana Biotechnology Announces Plan to Relocate Manufacturing to Bothell, Washington Along with Key Executive Hires in Manufacturing and
Material agreement · New financial obligation · Other events · EX-99.1 to Form 8-K
Sana Biotechnology Reports First Quarter 2022 Financial Results and Business Updates
Results of operations · EX-99.1 to Form 8-K
Sana Biotechnology Reports Fourth Quarter and Full Year 2021 Financial Results and Business Updates
Results of operations · EX-99.1 to Form 8-K
Corporate Presentation January 2022 Exhibit 99.1
Material agreement · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K